By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on Recursion (RXRX), with key concerns being the company's high cash burn rate, limited revenue, and the binary risk associated with early-stage clinical programs REC-1245 and REC-4539. The '2028 runway' is questioned due to the inflationary nature of late-stage clinical trials and the potential for acceleration of trial timelines or failed programs.
Risk: High cash burn rate and the risk of dilution when moving into expensive, high-stakes clinical trials.
Opportunity: Potential licensing deals or proof of clinical efficacy for REC-1245 and REC-4539.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the
10 Best Penny Stocks to Buy for Long Term.
On May 14, 2026, Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $5.50 from $5 and kept an Equal Weight rating on the shares.
On May 6, 2026, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported Q1 EPS of (22c), versus the consensus estimate of (26c). Revenue totaled $6.47M, versus the consensus estimate of $15.78M. Cash, cash equivalents, and restricted cash stood at $665.2M, compared to $753.9M as of December 31, 2025. The company continues to expect its cash runway to extend into early 2028. CEO and President Najat Khan said the company is seeing strong momentum and execution across its portfolio, with increasing evidence that its integrated platform can translate biological and chemical insights into differentiated clinical programs. Khan added that recent developments, including initial safety and pharmacokinetic data from REC-1245 and the dosing of the first patient in REC-4539, represent additional proof points supporting the company’s end-to-end AI-driven drug discovery platform.
Last month, JPMorgan lowered the firm’s price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $10 from $11 previously and kept an Overweight rating on the shares.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company focused on using AI, automation, and data science to industrialize drug discovery.
While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Q1's large revenue shortfall and only marginal analyst target adjustments point to limited conviction in near-term value creation for RXRX."
Morgan Stanley's $0.50 price target hike to $5.50 on Recursion (RXRX) looks like faint praise after the stock's Q1 revenue came in at just $6.47M versus $15.78M expected, a 59% shortfall that raises questions about milestone timing and platform monetization. The EPS beat was minor and driven by lower costs, while cash fell from $754M to $665M with runway still projected into 2028. JPMorgan's separate cut from $11 to $10 underscores analyst caution. As a clinical-stage AI biotech with no approved products, RXRX remains highly sensitive to execution risk on early programs like REC-1245 and REC-4539 rather than broad validation.
The revenue miss could reflect deferred partnership payments rather than demand weakness, and the cash position plus CEO momentum comments might still support a re-rating if upcoming clinical data readouts hit.
"A 59% revenue miss, $88.7M quarterly cash burn, and Morgan Stanley's modest 10% raise despite management optimism signal the market is pricing in significant execution risk that the article's AI-narrative framing obscures."
Morgan Stanley's $5.50 target is a 10% raise on a stock trading near that level—modest conviction. More concerning: Q1 revenue missed consensus by 59% ($6.47M vs. $15.78M), EPS beat only because losses were smaller than feared. Cash burn is real ($88.7M in five months), pushing runway to early 2028—tight for a clinical-stage biotech. JPMorgan's recent downgrade to $10 (still above current price) suggests analyst disagreement. The 'strong momentum' rhetoric from management conflicts with revenue collapse. AI-drug-discovery narratives are crowded; execution risk on REC-1245 and REC-4539 is binary and unpriced into a $5.50 target.
If RXRX's platform truly industrializes drug discovery, early revenue miss may reflect timing of partnerships/licensing deals rather than platform failure, and $665M cash provides genuine runway for multiple shots on goal.
"The company’s massive revenue miss and high cash burn rate overshadow the modest price target increase, signaling significant execution risk for the AI-drug discovery model."
Recursion's Q1 revenue miss of nearly 60%—reporting $6.47M against a $15.78M consensus—is a glaring red flag for a company burning cash at this rate. While Morgan Stanley’s price target hike to $5.50 feels like a modest adjustment for liquidity, the $88.7M quarterly cash burn is unsustainable without dilution or a massive partnership milestone. The 'AI-driven drug discovery' narrative is popular, but the clinical data for REC-1245 and REC-4539 remains early-stage. Investors are essentially betting on a platform play that has yet to demonstrate a scalable revenue model. Until we see a significant licensing deal or proof of clinical efficacy, RXRX remains a speculative cash-burn story rather than a viable pharmaceutical business.
The bull case rests on the 'platform' value; if Recursion’s AI engine successfully identifies a single blockbuster molecule, the current valuation will look like a massive bargain compared to traditional, slower R&D models.
"The stock's upside depends on translating AI-driven discovery into approved therapies; without that clinical and regulatory translation, near-term revenue remains fragile and dilution risk looms."
From the article, Morgan Stanley nudges RXRX to a $5.50 target with an Equal Weight, but the Q1 print underscored real risk: the business remains far from profitability. Revenue of $6.47M missed the $15.78M consensus, and the cash runway, though stretched to early 2028, rests on a sparse cadence of clinical milestones rather than durable revenue. The AI-driven platform narrative is attractive but unproven at scale; downside pressures include clinical trial failures, dilution from future financings, and the biotech sector's high failure rate. The article’s promotional framing and penny-stock branding obscure execution risk and the steep FDA hurdle that may never materialize, despite early data.
Misses in Q1 could be a timing issue. Strong early safety/PK signals could de-risk the platform enough to catalyze partnerships and capital efficiency, potentially supporting a re-rating.
"Extended cash runway to 2028 reduces immediate dilution risk that Gemini flags."
The $665M cash position and 2028 runway noted by Grok and Claude undercuts Gemini's claim of unsustainable burn requiring near-term dilution. Platform revenue is inherently lumpy from milestone timing rather than recurring sales, so the 59% miss alone does not prove demand weakness. This extended window allows multiple REC-1245 and REC-4539 readouts before capital raises, a buffer most peers lack and one the targets from $5.50 to $10 already appear to embed.
"Extended runway is illusory if clinical burn rates exceed partnership milestone timing."
Grok's runway math is correct, but obscures a harder question: does $665M cash actually fund multiple readouts, or does it fund expensive Phase 2 trials that consume $30–50M per program annually? Two parallel programs at clinical stage burn faster than milestone-driven revenue arrives. The 2028 runway assumes no acceleration of trial timelines or failed programs forcing restarts. That's not a buffer—it's a tightrope.
"The projected 2028 cash runway is misleading because it fails to account for the exponential cost increases associated with advancing clinical-stage programs into pivotal trials."
Claude, you’re hitting the crux: the '2028 runway' is a vanity metric. It assumes a static cost structure that ignores the inflationary nature of late-stage clinical trials. If RXRX moves REC-1245 or REC-4539 into pivotal trials, their burn rate will decouple from current projections. The market isn't pricing in the 'platform'—it's pricing in the inevitable dilution that occurs when cash-burning biotechs reach the expensive, high-stakes phase of clinical development. The runway is a mirage.
"Burn-rate math conflicts with the claimed 2028 runway, tightening buffer for readouts and raising near-term dilution risk."
Claude argued $665M cash buys genuine runway into 2028, implying a multi-year buffer for readouts. However, the article notes an $88.7M burn in five months, roughly $213M/year. At that pace, $665M funds only about 3 years of operations, not a long runway. That tightens the timeline for REC-1245/REC-4539 milestones and heightens near-term dilution risk, unless milestone cash inflows accelerate far faster than modeled. This math deserves skepticism.
The panel consensus is bearish on Recursion (RXRX), with key concerns being the company's high cash burn rate, limited revenue, and the binary risk associated with early-stage clinical programs REC-1245 and REC-4539. The '2028 runway' is questioned due to the inflationary nature of late-stage clinical trials and the potential for acceleration of trial timelines or failed programs.
Potential licensing deals or proof of clinical efficacy for REC-1245 and REC-4539.
High cash burn rate and the risk of dilution when moving into expensive, high-stakes clinical trials.